GENE ONLINE|News &
Opinion
Blog

2021-10-21| ChinaIPO

Shanghai Startup Poised for $325M IPO on Nasdaq

by Tyler Chen
Share To
With just 2 years into operation, Shanghai startup LianBio is set to go public on the Nasdaq. The firm release the term for the initial public offering (IPO) on Oct. 20, and it plans to raise $325 million to complete Phase 3 clinical trials of its lead drug candidates.

LianBio said it will launch 20 million shares with $15 to $17 per share and a 30-day option to purchase up to an additional 3 million shares.

GO Prime with only $1.49 now

LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top